Brainreader Secures $6.6M to Accelerate Neuroreader® Innovation in Automated Brain Imaging

We are thrilled to announce that Brainreader has successfully raised $6,600,000 in funding, marking a significant milestone in our mission to revolutionize neuroimaging diagnostics. As the inventor of Neuroreader®, our breakthrough medical image processing software, we deliver automated labeling, visualization, and volumetric quantification of brain structures from MRI scans in under 10 minutes per analysis. Neuroreader® provides clinicians with clinically relevant quantitative data that is vital for early detection and precise monitoring of neurodegenerative diseases. With its comprehensive suite of features—including detailed heat maps, full brain structure analyses, longitudinal reporting, and asymmetry index measurements—our software stands out as a fast, accurate, low-cost, and non-invasive support tool for assessing structural MRIs. This new round of investment will propel Brainreader’s continued research and development, enabling us to further perfect Neuroreader®’s capabilities and broaden its global availability. Backed by FDA clearance, CE marking, and HIPAA compliance, our technology utilizes 3D T1 images with 1mm slices obtained during routine MRI scans, ensuring the highest standards of reliability and patient safety. Our investors share our commitment to harnessing advanced imaging technology to improve diagnostic accuracy and augment clinical decision-making. As we chart the future of neuroimaging, the raised capital positions us to accelerate product enhancements, extend market reach, and ultimately improve patient outcomes by empowering medical professionals with precise and rapid brain image analyses. Today’s funding is not just an investment in technology—it is an investment in a healthier future for patients worldwide, and we are excited to continue leading the way in innovative neurodegenerative disease diagnostics.